4xo6: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 3: / Line 3: @@
 <StructureSection load='4xo6' size='340' side='right'caption='[[4xo6]], [[Resolution|resolution]] 1.20&Aring;' scene=''>
 == Structural highlights ==
-<table><tr><td colspan='2'>[[4xo6]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4XO6 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4XO6 FirstGlance]. <br>
+<table><tr><td colspan='2'>[[4xo6]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4XO6 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4XO6 FirstGlance]. <br>
-</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=5SD:5ALPHA-ANDROSTAN-3,17-DIONE'>5SD</scene>, <scene name='pdbligand=AOX:(3BETA,5ALPHA)-3-HYDROXYANDROSTAN-17-ONE'>AOX</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.2&#8491;</td></tr>
-<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4l1w|4l1w]], [[4l1x|4l1x]], [[4xo7|4xo7]]</td></tr>
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5SD:5ALPHA-ANDROSTAN-3,17-DIONE'>5SD</scene>, <scene name='pdbligand=AOX:(3BETA,5ALPHA)-3-HYDROXYANDROSTAN-17-ONE'>AOX</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">AKR1C2, DDH2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4xo6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4xo6 OCA], [https://pdbe.org/4xo6 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4xo6 RCSB], [https://www.ebi.ac.uk/pdbsum/4xo6 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4xo6 ProSAT]</span></td></tr>
-<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4xo6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4xo6 OCA], [http://pdbe.org/4xo6 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4xo6 RCSB], [http://www.ebi.ac.uk/pdbsum/4xo6 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4xo6 ProSAT]</span></td></tr>
 </table>
 == Disease ==
-[[http://www.uniprot.org/uniprot/AK1C2_HUMAN AK1C2_HUMAN]] Defects in AKR1C2 are a cause of 46,XY sex reversal type 8 (SRXY8) [MIM:[http://omim.org/entry/614279 614279]]. A disorder of sex development. Affected individuals have a 46,XY karyotype but present as phenotypically normal females.<ref>PMID:21802064</ref>
+[https://www.uniprot.org/uniprot/AK1C2_HUMAN AK1C2_HUMAN] Defects in AKR1C2 are a cause of 46,XY sex reversal type 8 (SRXY8) [MIM:[https://omim.org/entry/614279 614279]. A disorder of sex development. Affected individuals have a 46,XY karyotype but present as phenotypically normal females.<ref>PMID:21802064</ref>
 == Function ==
-[[http://www.uniprot.org/uniprot/AK1C2_HUMAN AK1C2_HUMAN]] Works in concert with the 5-alpha/5-beta-steroid reductases to convert steroid hormones into the 3-alpha/5-alpha and 3-alpha/5-beta-tetrahydrosteroids. Catalyzes the inactivation of the most potent androgen 5-alpha-dihydrotestosterone (5-alpha-DHT) to 5-alpha-androstane-3-alpha,17-beta-diol (3-alpha-diol). Has a high bile-binding ability.<ref>PMID:8573067</ref>
+[https://www.uniprot.org/uniprot/AK1C2_HUMAN AK1C2_HUMAN] Works in concert with the 5-alpha/5-beta-steroid reductases to convert steroid hormones into the 3-alpha/5-alpha and 3-alpha/5-beta-tetrahydrosteroids. Catalyzes the inactivation of the most potent androgen 5-alpha-dihydrotestosterone (5-alpha-DHT) to 5-alpha-androstane-3-alpha,17-beta-diol (3-alpha-diol). Has a high bile-binding ability.<ref>PMID:8573067</ref>
-<div style="background-color:#fffaf0;">
-== Publication Abstract from PubMed ==
-Human 3alpha-HSD3 (3alpha-hydroxysteroid dehydrogenase type 3) plays an essential role in the inactivation of the most potent androgen 5alpha-DHT (5alpha-dihydrotestosterone). The present study attempts to obtain the important structure of 3alpha-HSD3 in complex with 5alpha-DHT and to investigate the role of 3alpha-HSD3 in breast cancer cells. We report the crystal structure of human 3alpha-HSD3.NADP(+).A-dione (5alpha-androstane-3,17-dione)/epi-ADT (epiandrosterone) complex, which was obtained by co-crystallization with 5alpha-DHT in the presence of NADP(+) Although 5alpha-DHT was introduced during the crystallization, oxidoreduction of 5alpha-DHT occurred. The locations of A-dione and epi-ADT were identified in the steroid-binding sites of two 3alpha-HSD3 molecules per crystal asymmetric unit. An overlay showed that A-dione and epi-ADT were oriented upside-down and flipped relative to each other, providing structural clues for 5alpha-DHT reverse binding in the enzyme with the generation of different products. Moreover, we report the crystal structure of the 3alpha-HSD3.NADP(+).4-dione (4-androstene-3,17-dione) complex. When a specific siRNA (100 nM) was used to suppress 3alpha-HSD3 expression without interfering with 3alpha-HSD4, which shares a highly homologous active site, the 5alpha-DHT concentration increased, whereas MCF7 cell growth was suppressed. The present study provides structural clues for 5alpha-DHT reverse binding within 3alpha-HSD3, and demonstrates for the first time that down-regulation of 3alpha-HSD3 decreases MCF7 breast cancer cell growth.
-Human 3alpha-hydroxysteroid dehydrogenase type 3: structural clues of 5alpha-DHT reverse binding and enzyme down-regulation decreasing MCF7 cell growth.,Zhang B, Hu XJ, Wang XQ, Theriault JF, Zhu DW, Shang P, Labrie F, Lin SX Biochem J. 2016 Apr 15;473(8):1037-46. doi: 10.1042/BCJ20160083. Epub 2016 Feb, 29. PMID:26929402<ref>PMID:26929402</ref>
-From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-</div>
-<div class="pdbe-citations 4xo6" style="background-color:#fffaf0;"></div>
 ==See Also==
@@ Line 29: / Line 19: @@
 __TOC__
 </StructureSection>
-[[Category: Human]]
+[[Category: Homo sapiens]]
 [[Category: Large Structures]]
-[[Category: Hu, X J]]
+[[Category: Hu X-J]]
-[[Category: Lin, S X]]
+[[Category: Lin S-X]]
-[[Category: Zhang, B]]
+[[Category: Zhang B]]
-[[Category: Akr]]
-[[Category: Akr1c2]]
-[[Category: Aldo-keto reductase]]
-[[Category: Alpha-beta barrel]]
-[[Category: Human 3-alpha hds3]]
-[[Category: Nadph]]
-[[Category: Oxidoreductase]]